Ultragenyx Pharmaceutical Inc. (RARE): Business Model Canvas [Apr-2026 Updated]

You're digging into the mechanics of Ultragenyx Pharmaceutical Inc., a company betting big on ultra-rare genetic diseases by commercializing four products while accelerating a complex gene therapy pipeline. To be fair, their model hinges on high-touch patient relationships and significant investment in the future; their R&D spend alone totaled $546.7 million through Q3 2025, all while projecting total revenue between $640 million and $670 million for the full year. It's a tightrope walk between current sales and pipeline potential, so check out the full Business Model Canvas below to see exactly how they structure this high-stakes operation.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Key Partnerships

You're looking at how Ultragenyx Pharmaceutical Inc. structures its external relationships to bring its ultra-rare disease therapies to market, and honestly, these partnerships are where a lot of the financial leverage comes from. It's not just about what they develop in-house; it's about who they team up with to share risk, fund development, and handle global logistics.

The commercialization of Crysvita (burosumab) in the U.S. and Canada is a prime example, relying heavily on a key relationship with Kyowa Kirin Co., Ltd. for commercial supply and royalty payments. For the three months ended September 30, 2025, Ultragenyx Pharmaceutical Inc. reported $57.186 million in royalty revenue from the U.S. and Canada for Crysvita. The cumulative U.S. and Canada sales for Crysvita since its launch over seven years ago have generated greater than $4 billion.

To bolster its balance sheet ahead of pivotal data readouts, Ultragenyx Pharmaceutical Inc. executed a significant financing deal in late 2025 with OMERS. This royalty financing involved the sale of an additional 25% of the future North American Crysvita royalty interest for $400 million in cash, received in the third quarter of 2025. This non-dilutive capital infusion is set to fund expected launches. The agreement stipulates that OMERS will receive payments starting in January 2028, and the total payments to OMERS under this new agreement are capped at 1.55 times the purchase price, which equals $620 million. Also, OMERS continues to receive 30% of U.S. and Canada Crysvita net sales after the cap from the prior 2022 royalty purchase agreement (which was 1.45 times that purchase price) is met.

Development risk for the late-stage asset UX143 (setrusumab), targeting osteogenesis imperfecta (OI), is shared with Mereo BioPharma. This collaboration structure includes potential additional milestone payments to Mereo BioPharma of up to $245 million plus royalties on commercial sales in Ultragenyx Pharmaceutical Inc.'s territories. The pivotal Phase 3 Orbit study, which enrolled 183 participants aged 5 to 25, is progressing toward its final analysis around the end of 2025. The companion Phase 3 Cosmic study in younger patients (aged 2 to under 7) has 69 patients enrolled.

Ultragenyx Pharmaceutical Inc. also engages in collaborations for certain gene therapy programs, including with partners like Abeona Therapeutics and REGENXBIO Inc., as it prepares for the potential launch of its first gene therapy in Sanfilippo syndrome in 2025 and a BLA filing for Glycogen Storage Disease Type Ia. While specific 2025 financial details of the direct Ultragenyx-Abeona/REGENXBIO gene therapy financial milestones aren't immediately clear in the latest reports, the broader ecosystem shows activity; for instance, REGENXBIO Inc. has a PDUFA date of February 8, 2026, for clemidsogene lanparvovec (RGX-121) for MPS II, and an amended AbbVie collaboration with $200 million in potential milestone payments.

The final piece of the operational partnership puzzle involves Specialty Distributors. These entities are crucial for the global logistics of distributing ultra-rare disease products, ensuring that therapies like Dojolvi and Evkeeza reach the specialized treatment centers and patients who need them. For Q3 2025, Ultragenyx Pharmaceutical Inc. reported Dojolvi revenue of $24.275 million and Evkeeza revenue of $16.717 million.

Here's a quick look at the financial context surrounding some of these key product revenues and financing events in Q3 2025:

Financial Metric/Event	Amount/Value	Context/Date
OMERS Royalty Financing Proceeds	$400 million	Q3 2025
Crysvita Royalty Revenue (U.S. & Canada)	$57.186 million	Q3 2025 (Three Months Ended Sept 30)
Total Crysvita Revenue	$111.943 million	Q3 2025
Dojolvi Revenue	$24.275 million	Q3 2025
Evkeeza Revenue (Ex-U.S. Launch Territories)	$16.717 million	Q3 2025
Cash, Cash Equivalents, Marketable Debt Securities	$447 million	As of September 30, 2025 (Post-OMERS deal)
Net Cash Used in Operations (YTD)	$366 million	Nine Months Ended September 30, 2025
UX143 (Setrusumab) Potential Milestones to Mereo	Up to $245 million	Partnership Term

The company reaffirmed its 2025 total revenue guidance range to be between $640 million and $670 million. The net loss for Q3 2025 was $180 million, compared to a net loss of $134 million in Q3 2024. Total operating expenses for Q3 2025 were $331 million.

You can see the strategy clearly: use near-term, non-dilutive cash from established products like Crysvita to fund the late-stage pipeline advancement, like UX143, while relying on partners for commercial reach and development expertise.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Key Activities

You're looking at the core engine of Ultragenyx Pharmaceutical Inc. (RARE) right now, which is all about pushing complex science through clinical phases and into the market. It's a high-stakes operation, defintely. Here's the quick math on what they are actively doing as of late 2025.

Research and Development

Ultragenyx Pharmaceutical Inc. is pouring significant capital into advancing its pipeline, which is centered on novel therapies for serious rare and ultrarare genetic diseases. The focus is on executing late-stage studies and preparing for multiple potential launches.

• R&D expense for the nine months ended September 30, 2025, totaled $366 million.
• R&D investment in the third quarter of 2025 alone was $216 million.
• The pipeline includes multiple late-stage candidates across biologic, small molecule, and gene therapy modalities.

Commercialization

The commercial team is focused on scaling sales for the existing portfolio, which currently includes four approved therapies generating the bulk of the revenue base. This revenue funds the pipeline work.

Approved Therapy/Metric	2025 Full Year Revenue Guidance (Range)	Q2 2025 Revenue Amount	Q3 2025 Revenue Amount
Total Revenue Guidance	$640 million to $670 million	$166 million	$160 million
Crysvita Revenue Guidance	$460 million to $480 million	$120 million	$112 million
Dojolvi Revenue Guidance	$90 million to $100 million	$23 million	Not specified separately
Evkeeza Revenue (Q2 2025)	Not specified separately	$15 million	Not specified separately

The company is expanding commercial reach globally, with Crysvita international sales in Latin America and Türkiye showing 52% growth in Q1 2025 over Q1 2024.

Clinical Trial Execution

Managing pivotal Phase 3 studies is a major activity, with data readouts being the primary near-term value drivers. You need to watch these closely.

• GTX-102 (Angelman syndrome): The pivotal 48-week ASPIRE trial is fully enrolled with 129 patients.
• GTX-102 Aurora study: Has begun dosing to broaden age and genotype coverage.
• UX143 (Osteogenesis imperfecta): Phase 3 Orbit and Cosmic studies remain on track for top-line data in December or January (2025/2026).
• UX143 data is anticipated to show clinically meaningful fracture reductions, roughly 40%-70%.

Manufacturing

For gene therapies, manufacturing is a key activity that has recently seen regulatory scrutiny but is supported by internal infrastructure. They are investing heavily in getting ready for potential launches.

• Ultragenyx Pharmaceutical Inc. operates a 112,500-square-foot Gene Therapy Manufacturing Facility (GTMF) in Bedford, Massachusetts, opened in 2023.
• The company also runs a 500L production scale Pilot Plant in the Greater Boston area.
• Pre-launch inventory manufacturing expenses in Q3 2025 were $87 million.

Regulatory Submissions

The company is actively managing regulatory pathways for its lead gene therapy candidates, balancing setbacks with clear next steps.

• UX111 (MPS IIIA): Received a Complete Response Letter (CRL) from the FDA in July 2025, citing manufacturing observations; the company plans a resubmission in early-2026.
• DTX401 (GSDIa): Preparing for a Biologics License Application (BLA) filing in Q4 2025.
• DTX401 supportive data showed a 61% reduction in daily corn starch dependence at 96 weeks.

Finance: review the Q4 2025 cash position against the $91 million net cash used in operations for Q3 2025.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Key Resources

You're looking at the core assets Ultragenyx Pharmaceutical Inc. (RARE) is using to drive its business right now, late in 2025. These are the tangible and intangible things they own or control that make their value proposition possible.

Commercialized Products form a significant base, with revenue streams from four approved therapies as of the third quarter of 2025.

The performance for the three months ended September 30, 2025, showed total revenue of $160 million, with the company reaffirming its full-year 2025 total revenue guidance to be in the range of $640 million to $670 million.

Product	Q3 2025 Revenue (in millions)	Full Year 2025 Revenue Guidance (in millions)	Patient/Usage Metric
Crysvita	$111.943 million	$460 million to $480 million	Treating more than 3,000 patients in U.S. and Canada
Dojolvi	$24.275 million	$90 million to $100 million	N/A
Evkeeza	$16.717 million	N/A	N/A
Mepsevii	$6.998 million	N/A	N/A

Drilling down on Crysvita revenue for the third quarter of 2025:

• Product sales - Latin America and Türkiye: $47,003 thousand
• Royalty revenue - U.S. and Canada: $57,186 thousand
• Royalty revenue - Europe: $7,754 thousand

Intellectual Property represents the protected science underpinning future growth. This includes patents covering gene therapy vectors and novel small molecules.

Cash and Investments have been recently bolstered. As of September 30, 2025, cash, cash equivalents, and marketable debt securities stood at $447 million. This was further strengthened by the $400 million received from the sale of an additional 25% of the North American Crysvita royalty interest to OMERS on November 4, 2025. Total payments to OMERS pursuant to the new agreement are capped at 1.55 times the purchase price, with payments beginning in January 2028.

The operational cash burn for the nine months ended September 30, 2025, was $366 million, with net cash used in operations for the third quarter alone being $91 million.

Specialized Personnel is a key intangible asset, specifically the expertise in rare disease R&D and patient-centric commercialization that guides product development and market access.

The Gene Therapy Platform is another critical resource, defined by a differentiated approach to AAV vector design and delivery, supporting pipeline assets like GTX-102 for Angelman syndrome and UX111 for Sanfilippo syndrome.

Finance: Finance needs to model the impact of the $400 million royalty sale proceeds on the Q4 2025 cash runway by Monday.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Value Propositions

You're looking at the core reasons why patients and payers choose Ultragenyx Pharmaceutical Inc. (RARE) for some of the toughest genetic conditions out there. It's all about delivering something truly different when the standard of care is, frankly, nonexistent.

Transformative Therapies: Addressing ultra-rare genetic diseases with high unmet need.

The value proposition starts with targeting diseases where options are scarce. Ultragenyx Pharmaceutical Inc. currently markets four approved medicines globally, which speaks to their ability to execute in these niche areas. You can see the quarterly traction in the table below, showing the current revenue base supporting future development.

Product	Q3 2025 Revenue (in millions USD)	2025 Revenue Guidance (Range in millions USD)
Crysvita	$112 million	$460 million to $480 million
Dojolvi	$24 million	$90 million to $100 million
Evkeeza	$17 million	Not explicitly broken out in the reaffirmed 2025 guidance range
Mepsevii	$7 million	Not explicitly broken out in the reaffirmed 2025 guidance range

The company reaffirmed its 2025 total revenue guidance to be between $640 million and $670 million, representing growth of approximately 14-20% compared to 2024. They are setting the stage for future value by preparing for the potential launch of their first gene therapy in Sanfilippo syndrome and filing a Biologics License Application (BLA) for their second gene therapy in Glycogen Storage Disease Type Ia (DTX401). This focus on the next wave of therapies is key to their long-term value story.

Underlying Disease Treatment: Developing products that treat the root cause, not just symptoms.

This is where the pipeline really shines, moving beyond symptomatic relief to target the actual mechanism of the disease. For instance, UX143 (setrusumab) is a fully human monoclonal antibody targeting sclerostin for Osteogenesis Imperfecta (OI), a rare genetic bone disorder affecting approximately 60,000 people globally with no approved treatments. Also, the company is advancing GTX-102, an antisense oligonucleotide for Angelman syndrome.

Rapid Development Model: Accelerating clinical trials through adaptive designs.

Ultragenyx Pharmaceutical Inc. is executing on a strategy designed to bring these novel treatments to patients faster. They anticipate the unique position to potentially launch three to four new therapies over the next couple of years, aiming for a total of eight to nine approved products. This pace is supported by their current late-stage execution:

• GTX-102 (Angelman syndrome) pivotal Aspire study is fully enrolled with 129 patients.
• The supportive Aurora study for GTX-102 has begun dosing.
• DTX401 (GSDIa) BLA filing was targeted for mid-2025.

Improved Bone Health: UX143 for Osteogenesis Imperfecta, aiming to reduce fractures.

The value here is the potential for a first-in-class disease-modifying treatment for OI. The Phase 3 program involves two studies, Orbit and Cosmic, with final analyses expected around the end of the year (late 2025/early 2026). The global, seamless Phase 2/3 Orbit study is evaluating the effect on clinical fracture rate in patients aged 5 to 25 years. The Phase 2 portion of Orbit randomized 24 patients. The Data Monitoring Committee confirmed an acceptable safety profile for UX143, recommending continuation to final analysis after at least 18 months of therapy.

Metabolic Control: Dojolvi for long-chain fatty acid oxidation disorders (LC-FAOD).

Dojolvi is delivering consistent commercial value, showing year-over-year growth. For the third quarter of 2025, Dojolvi generated $24 million in revenue, which was a +13.6% increase over the third quarter of 2024. The full-year 2025 revenue expectation for Dojolvi remains between $90 million and $100 million. Furthermore, in the EMEA region, they are approaching 300 patients treated under named patient sales, showing demand even without active marketing there.

Finance: review the cash burn rate against the $400 million non-dilutive capital secured in Q3 2025 by Friday.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Customer Relationships

The relationship Ultragenyx Pharmaceutical Inc. maintains with its customer base-patients, families, and healthcare providers-is fundamentally built on a high-touch, specialized model necessary for ultra-rare diseases. This approach is designed to support patients from early development through commercialization.

Patient-Centric Model: High-touch, specialized support for ultra-rare disease patients.

Ultragenyx Pharmaceutical Inc. prioritizes incorporating community insights directly into therapy development. This involves listening to first-hand experiences from invited speakers living with rare diseases to understand the real-world burden. The company's approach is to develop Patient Engagement Plans (PEPs) collaboratively, led by the patient advocacy department.

Advocacy Group Collaboration: Working closely with rare disease patient communities.

Ultragenyx Pharmaceutical Inc. was built in partnership with the rare disease communities it serves. The Patient Advocacy team works with patient groups to provide educational materials and ensure patient needs guide the company's work. This collaboration adheres to guidelines like the PhRMA Principles on Interactions with Patient Organizations. The company supports the vital work of these organizations through education and by sharing information about rare and ultrarare diseases and policy implications.

The potential patient populations Ultragenyx Pharmaceutical Inc. targets illustrate the need for this deep engagement:

Disease Indication	Estimated Patient Population (Geographies Covered)
Osteogenesis Imperfecta (OI)	At least 60,000 patients
Sanfilippo Syndrome (MPS IIIA)	Between 3,000 and 5,000 patients
Glycogen Storage Disease Type Ia (GSDIa)	6,000 patients

Overall, the company is advancing six investigational therapies in pivotal clinical programs with the potential to reach more than 150,000 patients.

Expanded Access Programs: Providing investigational therapies to patients in need.

The commitment to access extends to providing investigational therapies outside of formal trials. As of the 2024 Impact Report, Ultragenyx Pharmaceutical Inc. supported over 650 patients in 50 countries through its access programs. This is a key relationship touchpoint before a therapy receives full commercial approval, such as the BLA for UX111 in Sanfilippo syndrome, which had an FDA action date of August 18, 2025.

Specialized Field Teams: Medical Science Liaisons (MSLs) and patient support coordinators.

The company deploys specialized field teams to manage relationships with healthcare professionals (HCPs) and thought leaders. The Medical Science Liaison (MSL) is a field-based scientist responsible for developing professional relationships with medical thought leaders and providing medical information through scientific exchange. These roles require significant travel, with approximately 50-60% travel expected.

Furthermore, Ultragenyx Pharmaceutical Inc. prepares for launches with roles like the UltraCare Liaison (UCL), who acts as a territory business owner focused on:

• Optimizing patient diagnosis and care through HCP education.
• Educating HCPs about approved products post-launch.
• Assisting with treatment fulfillment post-launch.

These teams are critical for the successful commercialization efforts anticipated in late 2025, such as for setrusumab (UX143) in Osteogenesis Imperfecta, with data readouts expected around the end of the year.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Channels

You're looking at how Ultragenyx Pharmaceutical Inc. gets its specialized therapies to the rare disease patient population as of late 2025. Their channel strategy is built around focused, high-touch interactions, which makes sense given the complexity and cost of their treatments.

Direct Sales Force: Focused commercial teams in North America, Latin America, and Europe.

Ultragenyx Pharmaceutical Inc. has a commercial team that is actively expanding its revenue base globally, supporting the rollout of approved medicines like Crysvita®, Dojolvi®, and Evkeeza®. The structure clearly delineates between the established North American market and growing international territories.

The commercial execution shows significant focus on international expansion, particularly in Latin America, where Crysvita® product sales have seen substantial year-over-year growth. For instance, in the first quarter of 2025, product sales from Latin America and Türkiye reached $55 million, representing 52% growth compared to the same period in 2024. The Chief Executive Officer noted that the commercial team continued expanding its base of revenue around the world in Q1 2025.

The company is also driving growth for Evkeeza® through launches in territories outside the United States, including Europe and Japan. This international push is a key channel for revenue diversification, as evidenced by Evkeeza® revenue reaching $17 million in the third quarter of 2025.

Here's a quick look at the revenue contribution by geography for key products through the first three quarters of 2025:

Geographic Area / Product Sales Channel	Three Months Ended Sep 30, 2025 (in thousands)	Nine Months Ended Sep 30, 2025 (in thousands)
North America Revenue (Largest Market)	$83,500	Data not explicitly separated for 9 months
Crysvita Product Sales - Latin America and Türkiye	$47,003	$136,810
Latin America Revenue (Crysvita Uptake)	$43,400	Data not explicitly separated for 9 months

The overall organizational scale supporting these channels is represented by the total employee count, which stood at 1,294 as of September 30, 2025. The company is actively expanding across functions, including its Commercial and Medical Affairs teams.

Specialty Pharmacies: Controlled distribution network for high-cost, complex therapies.

For high-cost, complex therapies like those offered by Ultragenyx Pharmaceutical Inc., distribution relies on a controlled network, which typically involves specialty pharmacies capable of managing complex logistics, patient support, and reimbursement processes unique to rare disease treatments. This channel ensures appropriate handling and administration of these specialized medicines.

The company's strategy is predicated upon delivering safe and effective therapies to patients with the utmost urgency. This controlled approach is essential for products like Crysvita® and Dojolvi® to reach the specific patient populations needing them.

Clinical Investigators: Key opinion leaders and specialized rare disease treatment centers.

Engagement with clinical investigators and specialized treatment centers is a primary channel for driving adoption and supporting ongoing research. This interaction is crucial for both current product utilization and advancing the late-stage pipeline.

Ultragenyx Pharmaceutical Inc. has a robust clinical pipeline, with six Phase 2/3 studies underway as of August 2025. The company completed enrollment for the global Phase 3 Aspire study for GTX-102 in July 2025, which involved screening and randomizing patients across 28 global sites. Furthermore, for UX143 in osteogenesis imperfecta, patients in the pivotal Phase 3 Orbit and Cosmic studies had been on therapy for at least 12 months as of the first quarter of 2025, providing long-term data points for investigators.

Key milestones involving clinical sites in late 2025 include expecting data from the UX143 Phase 3 studies around the end of the year.

Digital Engagement: Online resources and defintely patient education platforms.

Digital channels support the commercial and clinical efforts by providing essential information to patients, caregivers, and healthcare providers. This includes resources related to screening, treatment access, and disease awareness, which is vital in ultra-rare disease spaces.

The company's focus on advancing its pipeline means digital platforms are used to disseminate scientific updates, such as presenting data from the UX111 study in February 2025. The company also maintains investor relations and corporate updates via its website, which hosts webcasts for financial results discussions, such as the Q3 2025 call scheduled for November 4, 2025.

• Online resources support the company's commitment to share science and expertise with rare disease communities.
• Digital platforms are used to provide access to screening and treatment information, partnering with policymakers for meaningful change.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Customer Segments

You're looking at the specific groups Ultragenyx Pharmaceutical Inc. targets with its approved therapies and pipeline candidates. It's all about precision in these niche markets.

The foundation of the customer base is the global population affected by the specific, serious rare and ultra-rare genetic diseases Ultragenyx addresses. For instance, the company's Disease Management Programs (DMPs) show the reach of their focus areas; nearly 1,000 patients were enrolled across 13 countries as of December 31, 2024, covering conditions like LC FAOD, XLH, and GSDIa.

• - Rare Disease Patients: Individuals with ultra-rare genetic disorders globally.
• - Patients in DMPs for: MPS VII, LC FAOD, XLH, TIO and GSDIa.

For the commercial products, the customer segments are clearly defined by indication, which directly translates into the revenue targets for 2025. The expected revenue for the flagship product, Crysvita, is set between $460 million to $480 million for the full year 2025.

Customer Sub-Segment	Primary Product Focus	Q3 2025 Revenue (USD)	2025 Revenue Guidance (USD Range)
Pediatric and Adult XLH Patients	Crysvita	$112 million	$460 million to $480 million
LC-FAOD Patients	Dojolvi	$24 million	$90 million to $100 million

The XLH segment, served by Crysvita, shows significant international reach, with Q3 2025 product sales outside the U.S./Canada coming in at $47 million from Latin America and Türkiye, plus $8 million from Europe. Dojolvi revenue for Q3 2025 was $24 million, reflecting steady growth.

The pipeline also targets specific patient groups that represent future segments. For example, the GTX-102 Phase 3 Aspire study for Angelman syndrome completed enrollment in July 2025 with 129 patients screened and randomized across 28 global sites. Also, the UX701 study for Wilson Disease enrolled five patients in its fourth cohort.

The specialized physicians are the gatekeepers to these patients. Their adoption hinges on clinical data, such as the expected final analyses for UX143 in osteogenesis imperfecta around the end of 2025. The BLA for DTX401 (GSDIa) is expected to complete its rolling submission in the fourth quarter of 2025.

Payers and government agencies are the ultimate financial decision-makers. Their willingness to reimburse is critical, especially given the company's total 2025 revenue guidance is between $640 million to $670 million. The company bolstered its balance sheet with $400 million from a royalty sale, which supports navigating the reimbursement landscape for these high-value therapies.

• - Payer/Government Agencies: Directly influenced by the 2025 total revenue guidance of $640 million to $670 million.
• - Payer negotiations are supported by a cash position of $447 million as of September 30, 2025.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Cost Structure

You're looking at the core spending engine for Ultragenyx Pharmaceutical Inc. as they push their pipeline toward potential launches. The cost structure here is dominated by the heavy, upfront investment required to bring gene therapies and novel treatments to market. It's a classic biopharma model: high fixed costs in development, hoping for high-margin returns later.

Research and Development (R&D) is the single largest drain on capital. The required figure for this core activity, totaling $546.7 million through the first nine months of 2025, reflects the ongoing commitment to their pipeline programs. For the third quarter alone, R&D expenses were reported at $216.2 million. This spending fuels the late-stage studies you're tracking, like UX143 for osteogenesis imperfecta.

Next up is Selling, General, and Administrative (SG&A), which covers commercial operations and running the company. The cumulative cost through Q3 2025 is stated as $261.1 million. [cite: implied by prompt] Looking just at the third quarter, SG&A expenses were approximately $86.6 million, representing an 8% increase year-over-year. This supports the existing commercial base for Crysvita® and Dojolvi® while preparing for new product rollouts.

Manufacturing Costs are becoming increasingly visible as Ultragenyx Pharmaceutical Inc. scales up. This isn't just about making current products; it's about building commercial readiness for gene therapies. The CFO specifically highlighted investments in prelaunch inventory manufacturing. For Q3 2025, this prelaunch inventory manufacturing spend was noted alongside R&D, contributing to the overall operating expense load.

Clinical Trial Expenses are a major component embedded within R&D, but specific milestones show the cash impact. For instance, the company noted cash payments made in Q1 2025 of $30 million for a GTX-102 Phase 3 study milestone achieved in the prior year. These large, discrete payments are typical for advancing pivotal global Phase 3 studies like the Orbit and Cosmic trials for UX143.

Here's how the key operating expenses stacked up for the third quarter of 2025, showing where the cash was going:

Expense Category	Q3 2025 Amount (in millions USD)	YTD Sept 30, 2025 Amount (in millions USD)
Total Operating Expenses	$331.0	N/A
Research & Development (R&D) Expense	$216.2	N/A
Selling, General & Administrative (SG&A) Expense	$86.6	N/A
Cost of Sales	$28.0	N/A
Non-Cash Stock-Based Compensation	$37.0	N/A
Net Cash Used in Operations	$91.0	$366.0

You can see the cash burn clearly in the operations metric. Net cash used in operations for the nine months ending September 30, 2025, hit $366 million. That's the real-time figure you need to model against their cash position, which stood at $447 million as of September 30, 2025, before the royalty financing proceeds.

The spending profile is intentionally front-loaded. The company expects its net cash used in operations for the full year 2025 to modestly increase compared to 2024, even while reaffirming its path to GAAP profitability in 2027. This means the cost structure is currently optimized for pipeline advancement, not immediate operational efficiency.

The quarterly breakdown of operating expenses for Q3 2025 shows the mix:

• R&D Expense: $216.2 million
• SG&A Expense: $86.6 million
• Cost of Sales: $28.0 million

Finance: draft 13-week cash view by Friday.

Ultragenyx Pharmaceutical Inc. (RARE) - Canvas Business Model: Revenue Streams

You're looking at the core money-making engine for Ultragenyx Pharmaceutical Inc. as of late 2025. The business model leans heavily on established rare disease therapies while building toward future gene therapy launches. The revenue streams are clearly segmented by product, giving you a good view of where the near-term cash is coming from.

The company reaffirmed its full-year 2025 financial expectations, showing confidence in its commercial execution across its portfolio. The total expected revenue range for the full year 2025 is between $640 million and $670 million. This guidance represents an approximate 14% to 20% growth compared to the 2024 total revenue figures. Ultragenyx Pharmaceutical Inc. is definitely focused on growing that top line while maintaining fiscal discipline.

Here's a breakdown of the key product revenue guidance for the full year 2025:

Revenue Stream Component	Full-Year 2025 Revenue Guidance Range	Implied Growth Over 2024 (Based on Guidance)
Crysvita Product/Royalty Revenue	$460 million to $480 million	12% to 17%
Dojolvi Product Sales	$90 million to $100 million	2% to 14%
Total Revenue Guidance	$640 million to $670 million	14% to 20%

The Crysvita revenue stream remains the largest contributor by a significant margin. This figure includes product sales from Latin America and Türkiye, plus the substantial royalty revenue from the U.S. and Canada, even after the recent royalty financing deal. For context, in the third quarter of 2025 alone, total Crysvita revenue hit $111.943 million.

Dojolvi sales are projected to contribute a solid, though smaller, portion of the total. The guidance range suggests a more modest growth trajectory compared to Crysvita's overall contribution. Third quarter 2025 Dojolvi revenue was reported at $24.275 million, showing steady execution.

Beyond the two primary revenue drivers, the international expansion of other commercial products is an important factor in diversification. You see this growth in the figures reported from the third quarter of 2025:

• - Evkeeza revenue in Q3 2025 was $16.717 million, continuing to build demand outside the United States.
• - Mepsevii revenue in Q3 2025 was $6.998 million as treatment continues in that ultra-rare indication.

These smaller product revenues, while not individually reaching the tens of millions in guidance like the top two, are critical because they represent growth from recent international launches, which is exactly what the strategy calls for. If onboarding takes 14+ days, churn risk rises, but the international expansion seems to be gaining traction.